Prognosis of invasive intraductal papillary mucinous neoplasms of the pancreas

作     者：Adam C Yopp Peter J Allen 

作者机构：Department of SurgeryDivision of Surgical OncologyUniversity of Texas Southwestern Medical Center5323 Harry Hines BoulevardDallasTX 75390United States Department of SurgeryMemorial Sloan-Kettering Cancer Center1275 York AvenueNew YorkNY 10065United States 

出 版 物：《World Journal of Gastrointestinal Surgery》 (世界胃肠外科杂志（英文版）（电子版）)

年 卷 期：2010年第2卷第10期

页      面：359-362页

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

主　　题：Intraductal papillary mucinous neoplasms Pancreatic adenocarcinoma Prognosis 

摘      要：Intraductal papillary mucinous neoplasms(IPMN) are mucin producing cystic neoplasms of the pancreas histologically classified as having non-invasive and invasive *** five-year survival rates for non-invasive and associated invasive carcinoma are 90% and 40%,respectively in resected IPMN *** carcinoma within IPMN lesions can be further classified by histological subtype into colloid carcinoma and tubular *** five-year survival rates following resection of colloid carcinoma range from 57%-83% and estimated five-year survival following resection of tubular carcinoma range from 24%-55%.The difference in survival outcome between invasive colloid and tubular IPMN appears to be a function of disease biology,as patients with the tubular subtype tend to have larger tumors with a propensity for metastasis to regional lymph *** matched to resected conventional pancreatic adenocarcinoma lesions by the Memorial Sloan Kettering Cancer Center pancreatic adenocarcinoma nomogram,the colloid carcinoma histological subtype has an improved estimated five-year survival outcome compared to conventional pancreatic adenocarcinoma,87% and 23%(P = 0.0001),*** lesions with the tubular carcinoma subtype overall have a similar five-year survival outcome compared to conventional pancreatic ***,when these groups were stratified by regional lymph node status patients with negative regional lymph nodes and the tubular subtype experienced significantly better survival than patients with a similar nodal status and ductal adenocarcinoma with estimated five-year survival rates of 73% and 27%(P = 0.01),respectively.